EP1667686A1 - Kombination vom serotonin wiederaufnahme hemmern und norepinephrin wiederaufnahme hemmern - Google Patents

Kombination vom serotonin wiederaufnahme hemmern und norepinephrin wiederaufnahme hemmern

Info

Publication number
EP1667686A1
EP1667686A1 EP04769269A EP04769269A EP1667686A1 EP 1667686 A1 EP1667686 A1 EP 1667686A1 EP 04769269 A EP04769269 A EP 04769269A EP 04769269 A EP04769269 A EP 04769269A EP 1667686 A1 EP1667686 A1 EP 1667686A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
halogen
optionally substituted
reuptake inhibitor
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP04769269A
Other languages
English (en)
French (fr)
Inventor
Megan Ann Pfizer Global R. and D. GIBBS
Jr. Earl Laux Pfizer Global R. and D. GILLER
Gerard Joseph Pfizer Global R. and D. MAREK
Robert Clyde Pfizer Global R. and D. MARSHALL
Tatiana Stanislavovna Pfizer Global R.& D. RAMEY
Erik Ho Fong Pfizer Global R. and D. WONG
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Products Inc
Original Assignee
Pfizer Products Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US10/769,018 external-priority patent/US20050014848A1/en
Priority claimed from US10/860,721 external-priority patent/US20050009927A1/en
Application filed by Pfizer Products Inc filed Critical Pfizer Products Inc
Publication of EP1667686A1 publication Critical patent/EP1667686A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants

Definitions

  • This invention is directed to a pharmaceutical compositions comprising a serotonin reuptake inhibitor or pharmaceutically acceptable salts thereof and a norepinephrine reuptake inhibitor or pharmaceutically acceptable salts thereof, and to methods of treatment with such a composition.
  • the serotonin reuptake inhibitor is sertraline or a pharmaceutically acceptable salt thereof
  • the norepinephrine reuptake inhibitor is [S,S]-reboxetine or a pharmaceutically acceptable salt thereof, wherein sertraline is present in an amount sufficient for dopamine reuptake inhibition, wherein the amount of sertraline is from about 150 mg to about 200 mg.
  • the acids which are used to prepare the pharmaceutically acceptable acid salts of the active compounds used in formulating the pharmaceutk cal compositions of this invention that are basic in nature are those which form non-toxi ⁇ c acid addition salts, i.e., salts containing pharmacologically acceptable anions.
  • the amount of the norepinephrine reuptake inhibitor or pharmaceutically acceptable salt thereof is preferably an amount effective in enhancing noradrenergic neurotransmission in a mammal.
  • the amount of the serotonin reuptake inhibitor is an amount sufficient for dopamine reuptake inhibition.
  • Affinity for the sertraline transporter (SERT) and for DAT transporter is determined by the amount of the ⁇ -CIT ligand that is displaced.
  • the extent of dopamine reuptake inhibition, measured by transporter displacement using ⁇ -CIT in combination with extracellular dopamine increase, is greater than the extent of placebo.
  • Another exemplary daily dose of the norepinephrine reuptake inhibitor is from about 25 mg to about 200 mg of maprotiline per unit dose, preferably between 50 mg and 150 mg of maprotiline per unit dose, which could be administered, for example 1 to 3 times per day.
  • An exemplary dose ratio by weight of a serotonin reuptake inhibitor to a norepinephrine reuptake inhibitor combination formulation for oral, parenteral or buccal administration to the average adult human for the treatment of the conditions referred to above is from about 0.00005 to about 20,000, preferably from about 0.25 to about 2,000.
EP04769269A 2003-09-09 2004-09-02 Kombination vom serotonin wiederaufnahme hemmern und norepinephrin wiederaufnahme hemmern Withdrawn EP1667686A1 (de)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US50127503P 2003-09-09 2003-09-09
US53889804P 2004-01-23 2004-01-23
US54069604P 2004-01-30 2004-01-30
US10/769,018 US20050014848A1 (en) 2002-01-23 2004-01-30 Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
US10/860,721 US20050009927A1 (en) 2002-01-23 2004-06-03 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
PCT/IB2004/002864 WO2005023265A1 (en) 2003-09-09 2004-09-02 Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors

Publications (1)

Publication Number Publication Date
EP1667686A1 true EP1667686A1 (de) 2006-06-14

Family

ID=34280166

Family Applications (1)

Application Number Title Priority Date Filing Date
EP04769269A Withdrawn EP1667686A1 (de) 2003-09-09 2004-09-02 Kombination vom serotonin wiederaufnahme hemmern und norepinephrin wiederaufnahme hemmern

Country Status (7)

Country Link
EP (1) EP1667686A1 (de)
BR (1) BRPI0413726A (de)
CA (1) CA2542339A1 (de)
MX (1) MXPA06002778A (de)
NL (1) NL1026989C2 (de)
TW (1) TW200526197A (de)
WO (1) WO2005023265A1 (de)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR042806A1 (es) 2002-12-27 2005-07-06 Otsuka Pharma Co Ltd Combinacion de derivados de carboestirilo e inhibidores de la reabsorcion de serotonina para el tratamiento de trastornos del animo
CA2511619C (en) 2002-12-27 2011-07-12 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives and serotonin reuptake inhibitors for treatment of mood disorders
AU2005256944A1 (en) * 2004-06-09 2006-01-05 Pfizer Inc. Use of reboxetine for the treatment of pain
JP6440625B2 (ja) 2012-11-14 2018-12-19 ザ・ジョンズ・ホプキンス・ユニバーシティー 精神分裂病を処置するための方法および組成物

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1499309A4 (de) * 2002-04-24 2008-05-28 Cypress Bioscience Inc Prävention und behandlung von funktionellen somatischen erkrankungen, einschliesslich stressbedingten erkrankungen

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2005023265A1 *

Also Published As

Publication number Publication date
NL1026989A1 (nl) 2005-03-10
MXPA06002778A (es) 2006-06-14
BRPI0413726A (pt) 2006-11-07
NL1026989C2 (nl) 2006-01-10
WO2005023265A1 (en) 2005-03-17
TW200526197A (en) 2005-08-16
CA2542339A1 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
TWI298255B (en) Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder
US6476078B2 (en) Methods of using sibutramine metabolites in combination with a phosphodiesterase inhibitor to treat sexual dysfunction
US5708035A (en) Methods of use and compositions of R(-) fluoxetine
JP5431136B2 (ja) 薬剤を製造するためのミルナシプランの（１ｓ，２ｒ）エナンチオマーの使用
NZ264774A (en) Use of fluoxetine, venlafaxine, milnacipran and duloxetine with a synergist in pharmaceutical compositions
JP2003523382A (ja) 新規な薬物の組合せ
PL219671B1 (pl) Zastosowanie enancjomeru (1S, 2R) milnacypranu do wytwarzania leku
JP5491475B2 (ja) ムスカリン性受容体ｍ１拮抗剤を使用する精神状態の処置
US20050014848A1 (en) Combination of serotonin reuptake inhibitors and norephinephrine reuptake inhibitors
KR20070051770A (ko) 자살경향성의 예방 또는 감소 및 자살경향성과 연관된 주요우울증의 치료를 위한 메만틴
EP0759299B1 (de) Potenzierung von Serotonin-Wirkstoffresponz
AU2011313814B2 (en) Combination therapy for the treatment of depression and other non-infectious diseases
EP3484461A1 (de) Kombinationen von adrenergen rezeptor-agonisten zur behandlung von typ-2-diabetes
EP0386117B1 (de) Behandlung des prämenstruellen oder späten lutealsphase-syndroms
US5958429A (en) Potentiation of serotonin response
TW200835477A (en) Methods for treating depression
US20050009927A1 (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
JP2013079277A (ja) ムスカリン性受容体ｍ１拮抗薬による肥満の処置
PROFILE Pharmacology of antidepressants: focus on nefazodone
WO2005023265A1 (en) Combination of serotonin reuptake inhibitors and norepinephrine reuptake inhibitors
JP2005513105A (ja) 臨床的うつ病を治療するためのデオキシペガニンの使用
RU2455981C2 (ru) Лечение ожирения антагонистами мускаринового рецептора м1
EA011650B1 (ru) Комбинация агомелатина и ингибитора обратного захвата норадреналина и фармацевтические композиции, которые её содержат
WO1992013452A1 (en) Methods of use and compositions of r(-) fluoxetine
WO2002076461A1 (en) Combination of reboxetine and citalopram

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20060410

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI LU MC NL PL PT RO SE SI SK TR

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20070412

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20070824